trending Market Intelligence /marketintelligence/en/news-insights/trending/0A5YjRns1bOdaV4-fhV25Q2 content esgSubNav
In This List

Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

The U.S. Food and Drug Administration granted orphan drug designation to Ovid Therapeutics Inc.'s TAK-935/OV935 to treat Lennox-Gastaut syndrome, a rare form of epilepsy.

In January, Takeda Pharmaceutical Co. Ltd. and Ovid formed a global collaboration to develop and commercialize TAK-935/OV935 to treat developmental and epileptic encephalopathies, a group of rare epilepsies that cause morbidities and can worsen over time.

The agency previously granted orphan drug status to the drug for the treatment of Dravet syndrome, another rare form of epilepsy.